(1)
Cancer facts and figures 2017. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html
Accessed 25.09.2020
(2)
Cancer facts and figures 2019. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2019.html
Accessed 25.09.2020
(3)
German guidelines for soft tissue sarcoma 2019. https://www.onkopedia.com/de/onkopedia/guidelines/weichgewebssarkome-maligne-weichgewebstumoren-des-erwachsenen/@@guideline/html/index.html
Accessed 25.09.2020
(4)
Gronchi A, Strauss DC, Miceli R, et al. Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working Group. Ann Surg. 2016;263(5):1002-1009. doi:10.1097/SLA.0000000000001447
(5)
Jakob, J., Lesluyes, T., Simeonova-Chergou, A. et al. Impact of preoperative treatment on the CINSARC prognostic signature: translational research results from a phase 1 trial of the German Interdisciplinary Sarcoma Group (GISG 03). Strahlenther Onkol 196, 280–285 (2020). https://doi.org/10.1007/s00066-019-01543-5
(6)
Kirste, S., Landenberger, N., Scholber, J. et al. Retroperitoneal soft tissue sarcoma: low-dose neoadjuvant radiation therapy followed by surgery with or without intraoperative radiotherapy and adjuvant radiation therapy. Strahlenther Onkol 195, 558–565 (2019). https://doi.org/10.1007/s00066-019-01464-3
(7)
Dunst J. Prä- oder postoperative Strahlentherapie bei retroperitonealen Sarkomen unverzichtbar [Pre- or postoperative radiotherapy essential for the treatment of retroperitoneal sarcomas]. Strahlenther Onkol. 2016;192(11):820-822. doi:10.1007/s00066-016-1042-4
(8)
Gilbeau L, Kantor G, Stoeckle E, et al. Surgical resection and radiotherapy for primary retroperitoneal soft tissue sarcoma. Radiother Oncol. 2002;65(3):137-143. doi:10.1016/s0167-8140(02)00283-9
(9)
O'Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359(9325):2235-2241. doi:10.1016/S0140-6736(02)09292-9
(10)
Bonvalot S, Gronchi A, Le Péchoux C, Swallow CJ, Strauss D, Meeus P, van Coevorden F, Stoldt S, Stoeckle E, Rutkowski P, Rastrelli M, Raut CP, Hompes D, De Paoli A, Sangalli C, Honoré C, Chung P, Miah A, Blay JY, Fiore M, Stelmes JJ, Dei Tos AP, Baldini EH, Litière S, Marreaud S, Gelderblom H, Haas RL. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020 Sep 14:S1470-2045(20)30446-0. doi: 10.1016/S1470-2045(20)30446-0. Epub ahead of print. PMID: 32941794.
(11)
Stubbe F, Agaimy A, Ott O, et al. Effective local control of advanced soft tissue sarcoma with neoadjuvant chemoradiotherapy and surgery: A single institutional experience. Cancer Radiother. 2016;20(1):6-13. doi:10.1016/j.canrad.2015.05.032
(12)
Common Terminology Criteria for Adverse Events 4.0. https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
Accessed 25.09.2020
(13)
Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731-1740. doi:10.1056/NEJMoa040694
(14)
Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926-1933. doi:10.1200/JCO.2011.40.1836
(15)
Shapiro J, van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090-1098. doi:10.1016/S1470-2045(15)00040-6
(16)
Sauer R, Schuchardt U, Hohenberger W, Wittekind C, Papadopoulos T, Grabenbauer GG, Fietkau R. Neoadjuvante Radiochemotherapie von Weichteilsarkomen. Optimierung der lokalen funktionserhaltenden Tumorkontrolle [Neoadjuvant radiochemotherapy in soft tissue sarcomas. Optimization of local functional tumor control]. Strahlenther Onkol. 1999 Jun;175(6):259-66. German. doi: 10.1007/BF02743576. PMID: 10392166.
(17)
Kraybill WG, Harris J, Spiro IJ, et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J Clin Oncol. 2006;24(4):619-625. doi:10.1200/JCO.2005.02.5577
(18)
Gronchi A, De Paoli A, Dani C, et al. Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: a phase I-II study from the Italian Sarcoma Group. Eur J Cancer. 2014;50(4):784-792. doi:10.1016/j.ejca.2013.11.021
(19)
De Sanctis R, Giordano L, Colombo C, De Paoli A, Navarria P, Sangalli C, Buonadonna A, Sanfilippo R, Bertola G, Fiore M, Marrari A, Navarria F, Bertuzzi A, Casali PG, Basso S, Santoro A, Quagliuolo V, Gronchi A. Long-term Follow-up and Post-relapse Outcome of Patients with Localized Retroperitoneal Sarcoma Treated in the Italian Sarcoma Group-Soft Tissue Sarcoma (ISG-STS) Protocol 0303. Ann Surg Oncol. 2017 Dec;24(13):3872-3879. doi: 10.1245/s10434-017-6105-y. Epub 2017 Oct 17. PMID: 29043525.
(20)
Gronchi A, Palmerini E, Quagliuolo V, Martin Broto J, Lopez Pousa A, Grignani G, Brunello A, Blay JY, Tendero O, Diaz Beveridge R, Ferraresi V, Lugowska I, Merlo DF, Fontana V, Marchesi E, Braglia L, Donati DM, Palassini E, Bianchi G, Marrari A, Morosi C, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Casali PG. Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. J Clin Oncol. 2020 Jul 1;38(19):2178-2186. doi: 10.1200/JCO.19.03289. Epub 2020 May 18. PMID: 32421444.
(21)
Issels RD, Lindner LH, Verweij J, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol. 2010;11(6):561-570. doi:10.1016/S1470-2045(10)70071-1
(22)
Issels RD, Lindner LH, Verweij J, et al. Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial [published correction appears in JAMA Oncol. 2018 Apr 1;4(4):590]. JAMA Oncol. 2018;4(4):483-492. doi:10.1001/jamaoncol.2017.4996